

Jani Sakari Saarela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1104048/publications.pdf>

Version: 2024-02-01

34
papers

1,102
citations

448610

19
h-index

488211

31
g-index

37
all docs

37
docs citations

37
times ranked

2001
citing authors

#	ARTICLE	IF	CITATIONS
1	Methods for High-throughput Drug Combination Screening and Synergy Scoring. <i>Methods in Molecular Biology</i> , 2018, 1711, 351-398.	0.4	140
2	APECED-causing mutations in AIRE reveal the functional domains of the protein. <i>Human Mutation</i> , 2004, 23, 245-257.	1.1	102
3	Prediction of drug combination effects with a minimal set of experiments. <i>Nature Machine Intelligence</i> , 2019, 1, 568-577.	8.3	99
4	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2022, 12, 388-401.	7.7	73
5	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. <i>Bioinformatics</i> , 2020, 36, 3602-3604.	1.8	68
6	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020, 26, 4107-4119.	3.2	68
7	Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations. <i>Human Molecular Genetics</i> , 2001, 10, 983-995.	1.4	57
8	Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1) – distinct characteristics in neurons. <i>BMC Cell Biology</i> , 2007, 8, 22.	3.0	42
9	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. <i>Clinical Cancer Research</i> , 2017, 23, 6697-6707.	3.2	41
10	Activation and Oligomerization of Aspartylglucosaminidase. <i>Journal of Biological Chemistry</i> , 1998, 273, 25320-25328.	1.6	40
11	Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. <i>Viruses</i> , 2017, 9, 271.	1.5	39
12	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. <i>Npj Systems Biology and Applications</i> , 2019, 5, 20.	1.4	32
13	The patatin-like lipase family in <i>Gallus gallus</i> . <i>BMC Genomics</i> , 2008, 9, 281.	1.2	30
14	A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase. <i>Human Mutation</i> , 2004, 24, 350-351.	1.1	26
15	Autoproteolytic activation of human aspartylglucosaminidase. <i>Biochemical Journal</i> , 2004, 378, 363-371.	1.7	25
16	BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine. <i>Scientific Reports</i> , 2016, 6, 28217.	1.6	23
17	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. <i>Chemistry and Biology</i> , 2015, 22, 1144-1155.	6.2	22
18	Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing. <i>Journal of the Association for Laboratory Automation</i> , 2016, 21, 27-36.	2.8	22

#	ARTICLE	IF	CITATIONS
19	High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro. <i>Biomolecules</i> , 2020, 10, 1365.	1.8	22
20	Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	22
21	Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 3274-3283.	2.5	19
22	Combined gene essentiality scoring improves the prediction of cancer dependency maps. <i>EBioMedicine</i> , 2019, 50, 67-80.	2.7	18
23	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. <i>Oncotarget</i> , 2017, 8, 18381-18398.	0.8	14
24	Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2015, 18, 3-17.	0.6	9
25	The High Throughput Biomedicine Unit at the Institute for Molecular Medicine Finland: High Throughput Screening Meets Precision Medicine. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2014, 17, 377-386.	0.6	9
26	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 14755.	1.6	7
27	Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	7
28	Avian phospholipid transfer protein causes HDL conversion without affecting cholesterol efflux from macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 781-789.	1.2	6
29	<i>In Vitro</i> Identification and <i>In Vivo</i> Confirmation of Inhibitors for Sweet Potato Chlorotic Stunt Virus RNA Silencing Suppressor, a Viral RNase III. <i>Journal of Virology</i> , 2021, 95, .	1.5	3
30	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. <i>Cancers</i> , 2021, 13, 2907.	1.7	3
31	Development of FRET-based high-throughput screening for viral RNase III inhibitors. <i>Molecular Plant Pathology</i> , 2020, 21, 961-974.	2.0	3
32	High Throughput siRNA Screening Using Reverse Transfection. <i>Methods in Molecular Biology</i> , 2016, 1470, 25-37.	0.4	1
33	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. <i>Blood</i> , 2017, 130, 854-854.	0.6	1
34	Genome-wide siRNA screening reveals several host receptors for the binding of human gut commensal <i>Bifidobacterium bifidum</i> . <i>Npj Biofilms and Microbiomes</i> , 2022, 8, .	2.9	1